325 related articles for article (PubMed ID: 32801270)
1. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.
Takai C; Ito S; Kobayashi D; Nemoto T; Lee H; Abe A; Otani H; Nakazono K; Murasawa A; Ishikawa H
Intern Med; 2020; 59(16):1963-1970. PubMed ID: 32801270
[TBL] [Abstract][Full Text] [Related]
2. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
Kurasawa T; Nagasawa H; Kishimoto M; Amano K; Takeuchi T; Kameda H
Mod Rheumatol; 2014 Jul; 24(4):561-6. PubMed ID: 24252035
[TBL] [Abstract][Full Text] [Related]
3. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
[TBL] [Abstract][Full Text] [Related]
4. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Ohnishi A; Kabata D; Hirano T; Hara R; Katayama M; Yoshida S; Nagai K; Son Y; Amuro H; Akashi K; Fujimura T; Hirao M; Yamamoto K; Shintani A; Kumanogoh A; Yoshikawa H
PLoS One; 2018; 13(3):e0194130. PubMed ID: 29543846
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
6. Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.
Rantalaiho V; Sandström T; Koski J; Hannonen P; Möttönen T; Kaipiainen-Seppänen O; Yli-Kerttula T; Kauppi MJ; Uutela T; Malmi T; Julkunen H; Laasonen L; Kautiainen H; Leirisalo-Repo M;
Arthritis Care Res (Hoboken); 2019 Nov; 71(11):1450-1458. PubMed ID: 30295425
[TBL] [Abstract][Full Text] [Related]
7. Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis.
Tanaka Y
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii15-ii22. PubMed ID: 27856656
[TBL] [Abstract][Full Text] [Related]
8. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.
Tanaka Y; Oba K; Koike T; Miyasaka N; Mimori T; Takeuchi T; Hirata S; Tanaka E; Yasuoka H; Kaneko Y; Murakami K; Koga T; Nakano K; Amano K; Ushio K; Atsumi T; Inoo M; Hatta K; Mizuki S; Nagaoka S; Tsunoda S; Dobashi H; Horie N; Sato N
Ann Rheum Dis; 2020 Jan; 79(1):94-102. PubMed ID: 31630117
[TBL] [Abstract][Full Text] [Related]
9. Six-month flare risk after discontinuing long-term methotrexate treatment in patients having rheumatoid arthritis with low disease activity.
Lee JS; Oh JS; Hong S; Kim YG; Lee CK; Yoo B
Int J Rheum Dis; 2020 Aug; 23(8):1076-1081. PubMed ID: 33021334
[TBL] [Abstract][Full Text] [Related]
10. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients.
Hamann PDH; Pauling JD; McHugh N; Shaddick G; Hyrich K;
Rheumatology (Oxford); 2019 Dec; 58(12):2162-2169. PubMed ID: 31155669
[TBL] [Abstract][Full Text] [Related]
11. An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.
Pope J; Rampakakis E; Vaillancourt J; Bessette L; Lazovskis J; Haraoui B; Sampalis JS
Rheumatology (Oxford); 2020 Jul; 59(7):1522-1528. PubMed ID: 31628486
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission.
Nawata M; Saito K; Nakayamada S; Tanaka Y
Mod Rheumatol; 2008; 18(5):460-4. PubMed ID: 18535759
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs.
Kobayashi D; Ito S; Takai C; Hasegawa E; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Mod Rheumatol; 2018 Jul; 28(4):599-605. PubMed ID: 28972441
[TBL] [Abstract][Full Text] [Related]
14. Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission.
Kameda H; Hirata A; Katagiri T; Takakura Y; Inoue Y; Takenaka S; Ito H; Mizushina K; Ogura T
Sci Rep; 2021 Mar; 11(1):6865. PubMed ID: 33767314
[TBL] [Abstract][Full Text] [Related]
15. An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients.
Ito S; Kobayashi D; Hasegawa E; Takai C; Nemoto T; Lee H; Abe A; Otani H; Ishikawa H; Murasawa A; Narita I; Nakazono K
Intern Med; 2019 Feb; 58(4):511-519. PubMed ID: 30210123
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab.
Dénarié D; Rinaudo-Gaujous M; Thomas T; Paul S; Marotte H
Mediators Inflamm; 2017; 2017():3708250. PubMed ID: 28352145
[No Abstract] [Full Text] [Related]
17. Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings.
Ochiai M; Tanaka E; Sato E; Inoue E; Abe M; Saka K; Sugano E; Sugitani N; Higuchi Y; Yamaguchi R; Sugimoto N; Ikari K; Nakajima A; Yamanaka H; Harigai M
Mod Rheumatol; 2021 Jul; 31(4):790-795. PubMed ID: 33538611
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
[TBL] [Abstract][Full Text] [Related]
19. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.
Wakabayashi H; Inada H; Nishioka Y; Hasegawa M; Nishioka K; Sudo A
Drugs R D; 2017 Mar; 17(1):233-239. PubMed ID: 28025727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
